| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥6199.5B | ¥6011.6B | +3.1% |
| Operating Income | ¥544.5B | ¥554.0B | -1.7% |
| Profit Before Tax | ¥589.4B | ¥610.9B | -3.5% |
| Net Income | ¥437.1B | ¥474.5B | -7.9% |
| ROE | 4.8% | 5.5% | - |
FY2026 Q3 results show Eisai achieving revenue of 619.9 billion yen (YoY +3.1%), while operating income decreased to 54.5 billion yen (YoY -1.7%), and net income attributable to owners declined to 41.8 billion yen (YoY -8.1%). The company maintained a high gross profit margin of 77.5%, but selling, general and administrative expenses reached 315.7 billion yen, compressing operating profitability. Operating cash flow of 57.2 billion yen exceeded net income by 1.37 times, confirming cash-backed earnings quality. Total assets increased to 1,486.2 billion yen from 1,386.5 billion yen, with equity ratio standing at 59.9%. The company faces challenges in profit growth despite revenue expansion, with elevated dividend payout and rising debt levels warranting attention.
Revenue growth of 3.1% to 619.9 billion yen reflects modest top-line expansion. The high gross profit margin of 77.5% demonstrates strong pricing power and product mix advantages in pharmaceutical operations. However, selling, general and administrative expenses increased to 315.7 billion yen, representing a growth rate that outpaced revenue expansion, resulting in operating income compression to 54.5 billion yen from 55.4 billion yen. The SG&A burden on revenue remains substantial, limiting operating leverage. Research and development expenses totaled 114.7 billion yen, maintaining the company's commitment to pipeline development. Operating income declined 1.7%, with operating margin at 8.8% compared to prior period levels. The gap between operating income of 54.5 billion yen and ordinary income levels reflects non-operating items including equity method investment gains and financial income. Net income of 43.7 billion yen decreased 7.9% year-over-year, with the effective tax rate at approximately 26%. This represents a revenue up, profit down pattern, driven by expense growth outpacing sales growth and indicating margin pressure requiring operational efficiency improvements.
[Profitability] Operating margin of 8.8% reflects the balance between strong gross margins and substantial SG&A expenses. Net profit margin stands at 6.7%, with ROE at 4.6%, showing room for improvement in capital efficiency compared to historical levels. The DuPont decomposition reveals ROE is driven by net profit margin of 6.7%, asset turnover of 0.417, and financial leverage of 1.62 times, with the low asset turnover representing the primary constraint on return metrics. [Cash Quality] Cash and equivalents total 319.4 billion yen, providing liquidity coverage, though the cash to short-term liabilities ratio warrants monitoring given the short-term debt composition. Operating cash flow to net income ratio of 1.37 times confirms earnings quality with cash backing. [Investment Efficiency] Asset turnover of 0.417 reflects high asset intensity, influenced by goodwill of 254.0 billion yen (17.1% of total assets), inventory of 243.7 billion yen, and receivables of 249.1 billion yen. Inventory turnover period extends to 639 days, significantly above optimal levels and indicating working capital efficiency challenges. [Financial Health] Equity ratio of 59.9% and current ratio of 8.67 times indicate solid financial stability. Debt-to-equity ratio stands at 0.25, with interest-bearing debt totaling 231.0 billion yen. However, short-term debt represents 41.7% of total debt, and long-term borrowings increased 35.0% to 134.8 billion yen, requiring attention to refinancing risk and interest burden management.
Operating cash flow of 57.2 billion yen represents 1.37 times net income of 43.7 billion yen, confirming cash-backed earnings quality. Investing cash flow included capital expenditures of 10.3 billion yen for property, plant and equipment and 4.4 billion yen for intangible assets, demonstrating continued investment in operational capacity and intellectual property. Financing activities included dividend payments of 45.1 billion yen and minimal share buybacks of 0.9 billion yen. Free cash flow generated 43.1 billion yen, yielding an FCF coverage ratio of 0.92 times against dividend payments, indicating dividends slightly exceed internally generated free cash. Cash and cash equivalents position of 319.4 billion yen provides adequate liquidity buffer, though the FCF dividend coverage below 1.0 times suggests current payout levels strain internal cash generation capacity without drawing on existing cash reserves.
Ordinary income levels compared to operating income of 54.5 billion yen show non-operating income contribution from equity method gains and financial income as components of the earnings structure. Non-operating income represents a modest portion of total revenue, consisting primarily of interest and dividend income alongside foreign exchange impacts. The tax-adjusted profit before tax of 58.9 billion yen with an effective tax rate of 25.8% indicates normal tax burden without unusual tax benefits distorting reported earnings. Operating cash flow exceeding net income by 37% demonstrates healthy earnings quality with strong cash realization. The absence of significant extraordinary items or impairment charges in the current period suggests recurring earnings character. Working capital metrics show elevated inventory and receivables positions requiring 639 days and 146 days turnover respectively, which while raising efficiency concerns, do not indicate aggressive accounting practices. Overall earnings quality appears sound on a cash basis, though operational efficiency in working capital management warrants improvement.
Full-year guidance maintains operating income forecast of 54.5 billion yen and net income attributable to owners of 41.5 billion yen. At Q3, the company has achieved operating income of 54.5 billion yen, representing 100.0% of the full-year target, while net income attributable to owners of 41.8 billion yen represents 100.7% of the full-year forecast. These progress rates significantly exceed the standard Q3 benchmark of 75%, indicating either conservative initial guidance or front-loaded earnings recognition. The YoY change assumptions embedded in guidance show operating income growth of 0.2%, net income decline of 10.6%, and profit before tax decline of 3.4%. The Q3 actual results align closely with full-year projections, suggesting limited incremental earnings expected in Q4. Investors should note the company appears on track to meet or slightly exceed guidance, with Q4 performance likely to be flat or slightly negative to achieve stated targets.
Annual dividend of 80.0 yen per share is maintained at prior year levels. Based on net income attributable to owners of 41.8 billion yen and estimated share count, the calculated payout ratio reaches 111.6%, exceeding net income and indicating dividends are being supported by operating cash flow and existing cash reserves rather than current period earnings alone. Share buyback activity during the period totaled 0.9 billion yen, representing minimal capital return through repurchases. Total shareholder returns combining dividends of 45.1 billion yen and buybacks of 0.9 billion yen amount to approximately 46.0 billion yen. Against free cash flow generation of 43.1 billion yen, the total return ratio exceeds 100%, confirming that current shareholder return levels draw upon balance sheet cash rather than being fully covered by period cash generation. This elevated payout structure warrants monitoring for sustainability, particularly if operating performance does not improve.
Elevated inventory levels with turnover period of 639 days present product obsolescence risk and working capital inefficiency, particularly in pharmaceutical operations where product lifecycles and regulatory approvals affect inventory valuation. This compares unfavorably to industry median of 282 days, indicating potential inventory management challenges or product mix issues requiring operational attention.
Short-term debt comprising 41.7% of total debt combined with debt coverage metrics creates refinancing risk exposure. With long-term borrowings increasing 35.0% to 134.8 billion yen, the company faces growing interest expense burden and refinancing requirements that could strain liquidity if credit market conditions tighten or operational cash flow deteriorates.
Goodwill balance of 254.0 billion yen representing 17.1% of total assets carries impairment risk if acquired businesses underperform expectations. Given the pharmaceutical industry's regulatory uncertainties and competitive dynamics, monitoring the carrying value of acquisition-related intangibles against business performance remains critical to avoid future impairment charges affecting reported earnings.
[Industry Position] (Reference - Proprietary Analysis)
Eisai's financial metrics show mixed positioning relative to pharmaceutical industry peers. Operating margin of 8.8% compares favorably to industry median of negative 218.2%, indicating the company maintains positive profitability while many industry participants report operating losses. ROE of 4.6% significantly outperforms industry median of negative 35.8%, demonstrating superior return generation despite the company's own room for improvement. Equity ratio of 59.9% falls below industry median of 67.8%, suggesting slightly higher financial leverage than typical pharmaceutical peers. Asset turnover of 0.417 exceeds industry median of 0.17, indicating more efficient asset utilization relative to the sector. Inventory turnover of 639 days substantially exceeds industry median of 282 days, highlighting working capital efficiency as a relative weakness requiring operational focus. Revenue growth of 3.1% compares favorably to industry median decline of 12.5%, positioning Eisai among growth-oriented pharmaceutical companies. The company's positive profitability metrics and revenue growth distinguish it within a pharmaceutical sector showing predominantly negative returns and declining sales among many participants.
(Source: Proprietary analysis of pharmaceutical industry, N=13 companies, 2025 Q3 comparison period)
Eisai demonstrates revenue resilience with 3.1% growth and industry-leading profitability metrics including operating margin of 8.8% and positive ROE of 4.6%, significantly outperforming pharmaceutical industry peers experiencing predominantly negative returns. The company's high gross profit margin of 77.5% reflects strong product pricing power and favorable mix, providing a solid foundation for earnings generation.
Operational efficiency challenges emerge from elevated SG&A expenses growing faster than revenue and inventory turnover of 639 days exceeding industry norms by over 100%, indicating working capital management requires improvement to enhance cash conversion and reduce capital intensity. The combination of dividend payout ratio exceeding 111% and FCF coverage of only 0.92 times raises sustainability questions regarding current shareholder return levels without operational improvements.
Balance sheet leverage metrics show mixed signals with comfortable equity ratio of 59.9% and moderate debt-to-equity of 0.25, but long-term debt increased 35% and short-term debt comprises 42% of total debt, creating refinancing risk exposure that warrants monitoring. The company's ability to maintain strong cash generation with operating CF exceeding net income by 37% provides reassurance, though free cash flow must improve to sustainably support current dividend policy without depleting cash reserves.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.